MUC1 Triggers Lineage Plasticity of Her2 Positive Mammary Tumors

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2022 Apr 24

PMID 35461328

Authors

Zhi Pang

Xinran Dong

Huayun Deng

Chengzhi Wang

Xiaodong Liao

Chunhua Liao

Yahui Liao

Weidong Tian

Jinke Cheng

Guoqiang Chen

Haiying Yi

Lei Huang

Affiliations

Soon will be listed here.

Abstract

Aberrant overexpression of mucin 1 (MUC1) and human epidermal growth factor receptor 2 (HER2) are often observed in breast cancer. However, the role of concomitant MUC1/HER2 in the development of breast cancer has not been fully illustrated. Following analysis of public microarray datasets that revealed a correlation between double MUC1 and HER2 positivity and a worse clinical outcome, we generated a mouse model overexpressing both Her2 and MUC1 cytoplasmic domain (MUC1-CD) to investigate their interaction in mammary carcinogenesis. Coexpression of Her2 and MUC1-CD conferred a growth advantage and promoted the development of spontaneous mammary tumors. Genomic analysis revealed that enforced expression of MUC1-CD and Her2 induces mammary tumor lineage plasticity, which is supported by gene reprogramming and mammary stem cell enrichment. Through gain- and loss-of-function strategies, we show that coexpression of Her2 and MUC1-CD is associated with downregulation of tricarboxylic acid (TCA) cycle genes in tumors. Importantly, the reduction in TCA cycle genes induced by MUC1-CD was found to be significantly connected to poor prognosis in HER2 breast cancer patients. In addition, MUC1 augments the Her2 signaling pathway by inducing Her2/Egfr dimerization. These findings collectively demonstrate the vital role of MUC1-CD/Her2 collaboration in shaping the mammary tumor landscape and highlight the prognostic and therapeutic implications of MUC1 in patients with HER2 breast cancer.

Citing Articles

Sha R, Dong X, Yan S, Dai H, Sun A, You L Sci Rep. 2024; 14(1):2908.

PMID: 38316885 PMC: 10844230. DOI: 10.1038/s41598-024-52638-8.

Novel 2-substituted-quinoxaline analogs with potential antiproliferative activity against breast cancer: insights into cell cycle arrest, topoisomerase II, and EGFR activity.

Salem M, Abu El-Ata S, Elsayed E, Mali S, Alshwyeh H, Almaimani G RSC Adv. 2023; 13(47):33080-33095.

PMID: 37954422 PMC: 10633821. DOI: 10.1039/d3ra06189b.

PEG-functionalized black phosphorus quantum dots as stable and biocompatible electrochemiluminescence luminophores for sensitive detection of tumor biomarker.

Liu J, Sun M, Li L, Chai Y, Kang Y, Yuan R Mikrochim Acta. 2023; 190(6):228.

PMID: 37204518 DOI: 10.1007/s00604-023-05768-1.

Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies.

Tian H, Zhang T, Qin S, Huang Z, Zhou L, Shi J J Hematol Oncol. 2022; 15(1):132.

PMID: 36096856 PMC: 9469622. DOI: 10.1186/s13045-022-01320-5.

References

Arteaga C, Sliwkowski M, Osborne C, Perez E, Puglisi F, Gianni L . Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011; 9(1):16-32. DOI: 10.1038/nrclinonc.2011.177. View

Moasser M . The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007; 26(45):6469-87. PMC: 3021475. DOI: 10.1038/sj.onc.1210477. View

Arkhipov A, Shan Y, Kim E, Dror R, Shaw D . Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family. Elife. 2013; 2:e00708. PMC: 3713454. DOI: 10.7554/eLife.00708. View

Damato V, Raimondo L, Formisano L, Giuliano M, De Placido S, Rosa R . Mechanisms of lapatinib resistance in HER2-driven breast cancer. Cancer Treat Rev. 2015; 41(10):877-83. DOI: 10.1016/j.ctrv.2015.08.001. View

Khodarev N, Pitroda S, Beckett M, MacDermed D, Huang L, Kufe D . MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. Cancer Res. 2009; 69(7):2833-7. PMC: 3034477. DOI: 10.1158/0008-5472.CAN-08-4513. View

Gendler S, Lancaster C, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J . Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem. 1990; 265(25):15286-93. View

Nath S, Mukherjee P . MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med. 2014; 20(6):332-42. PMC: 5500204. DOI: 10.1016/j.molmed.2014.02.007. View

Kufe D . MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment. Carcinogenesis. 2020; 41(9):1173-1183. PMC: 7513951. DOI: 10.1093/carcin/bgaa082. View

Kufe D . MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene. 2012; 32(9):1073-81. PMC: 3621754. DOI: 10.1038/onc.2012.158. View

10.

Schroeder J, Thompson M, GARDNER M, Gendler S . Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J Biol Chem. 2001; 276(16):13057-64. DOI: 10.1074/jbc.M011248200. View

11.

Schroeder J, Masri A, Adriance M, Tessier J, Kotlarczyk K, Thompson M . MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene. 2004; 23(34):5739-47. DOI: 10.1038/sj.onc.1207713. View

12.

Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe D . MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res. 2005; 65(22):10413-22. DOI: 10.1158/0008-5472.CAN-05-2474. View

13.

Raina D, Uchida Y, Kharbanda A, Rajabi H, Panchamoorthy G, Jin C . Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Oncogene. 2013; 33(26):3422-31. PMC: 3916940. DOI: 10.1038/onc.2013.308. View

14.

Li Y, Yi H, Yao Y, Liao X, Xie Y, Yang J . The cytoplasmic domain of MUC1 induces hyperplasia in the mammary gland and correlates with nuclear accumulation of β-catenin. PLoS One. 2011; 6(4):e19102. PMC: 3080410. DOI: 10.1371/journal.pone.0019102. View

15.

Li Y, Pang Z, Dong X, Liao X, Deng H, Liao C . MUC1 induces M2 type macrophage influx during postpartum mammary gland involution and triggers breast cancer. Oncotarget. 2018; 9(3):3446-3458. PMC: 5790475. DOI: 10.18632/oncotarget.23316. View

16.

Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Sakr R . In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nat Genet. 2015; 47(10):1212-9. PMC: 4589505. DOI: 10.1038/ng.3391. View

17.

Hanker A, Pfefferle A, Balko J, Kuba M, Young C, Sanchez V . Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc Natl Acad Sci U S A. 2013; 110(35):14372-7. PMC: 3761610. DOI: 10.1073/pnas.1303204110. View

18.

Wang D, Hu X, Liu C, Jia Y, Bai Y, Cai C . Protein C receptor is a therapeutic stem cell target in a distinct group of breast cancers. Cell Res. 2019; 29(10):832-845. PMC: 6796873. DOI: 10.1038/s41422-019-0225-9. View

19.

Raimundo N, Baysal B, Shadel G . Revisiting the TCA cycle: signaling to tumor formation. Trends Mol Med. 2011; 17(11):641-9. PMC: 3205302. DOI: 10.1016/j.molmed.2011.06.001. View

20.

Guo J, Zhang R, Yang Z, Duan Z, Yin D, Zhou Y . Biological Roles and Therapeutic Applications of IDH2 Mutations in Human Cancer. Front Oncol. 2021; 11:644857. PMC: 8107474. DOI: 10.3389/fonc.2021.644857. View